A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Kim, Gyungah; Choi, Eun Ji; Park, Han‐Seung; Lee, Jung‐Hee; Lee, Je‐Hwan; Lee, Kyoo‐Hyung

doi:10.3346/jkms.2021.36.e306

Cited by 15 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This interaction can lead to opsonization, triggering apoptosis in the adhered platelets, subsequently resulting in the clearance of antibody-coated platelets by the spleen. 49 Another possibility is that enhancement of macrophage-mediated clearance or impaired platelet production as a part of inflammatory response to COVID-19 vaccination may result in exacerbation of pre-existing, subclinical ITP. 50 …”

Section: Discussionmentioning

confidence: 99%

Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase

Kim,

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

Background During coronavirus disease 2019 (COVID-19) pandemic, several COVID-19 vaccines were licensed with fast-track procedures. Although these vaccines have demonstrated high immunogenicity, there has been concerns on the serious adverse events (AEs) following COVID-19 vaccination among adolescents. We aimed to analyze comparative safety of COVID-19 vaccination in adolescents. Methods In this pharmacovigilance study, we performed a disproportionality analysis using VigiBase, the World Health Organization’s global individual case safety report (ICSR) database. To compare serious AEs reported following COVID-19 vaccines vs. all other vaccines in adolescents aged 12–17 years, ICSRs following any vaccines on adolescents aged 12–17 years were included, defining cases as reports with the AEs of interest, with all other AEs as non-cases. The AEs of interest were myocarditis/pericarditis, multisystem inflammatory syndrome/Kawasaki disease (MIS/KD), anaphylaxis, Guillain-Barré syndrome (GBS), and immune thrombocytopenia (ITP). We conducted a disproportionality analysis to estimate reporting odds ratio (ROR) with 95% confidence interval (CI) for each AE of interest, adjusted for sex by using logistic regression. Results Of 99,735 AE reports after vaccination in adolescents, 80,018 reports were from COVID-19 vaccinated adolescents (52.9% females; 56.3% America). The AEs of interest were predominantly reported as serious AE (76.1%) with mRNA vaccines (99.4%). Generally, higher reporting odds for the AEs were identified following COVID-19 vaccination in adolescents; myocarditis/pericarditis (2,829 reports for the COVID-19 vaccine vs. 35 for all other vaccines, adjusted ROR [aROR], 19.61; 95% CI, 14.05–27.39), and MIS/KD (104 vs. 6, aROR, 4.33; 95% CI, 1.89–9.88). The reporting odds for anaphylaxis (515 vs. 165, aROR, 0.86; 95% CI, 0.72–1.02), GBS (94 vs. 40, aROR, 0.64; 95% CI, 0.44–0.92) and ITP (52 vs. 12, aROR, 1.12; 95% CI, 0.59–2.09) were not significantly higher following COVID-19 vaccination. Conclusion In this study, there were disproportionate reporting of immune-related AEs following COVID-19 vaccination. While awaiting definitive evidence, there is a need to closely monitor for any signs of immune-related AEs following COVID-19 vaccination among adolescents.

show abstract

Section: Discussionmentioning

confidence: 99%

Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase

Kim,

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…While most COVID‐19 vaccine‐associated ITP cases are reported after receiving mRNA vaccines, 11 Koch and his colleagues previously described a 41‐year‐old male with ITP, 14 days after the first dose of vaccination with AstraZeneca from Germany 6 . Furthermore, there were other reports of ITP 3 and 2 days after receiving AstraZeneca in a 66‐year‐old Korean female and a 25‐year‐old Iraqi male, respectively 14,15 . A case series reported 17 cases of secondary ITP related to AstraZeneca.…”

Section: Discussionmentioning

confidence: 99%

Relapse of immune thrombocytopenia after receiving AstraZeneca coronavirus disease‐2019 vaccine: A case report

Seyedi,

Navid,

Saadatian

2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…It has been suggested that portal infiltration with eosinophils correlates with drug-induced liver injury, including vaccines (i.e., Moderna mRNA-1273 and AstraZeneca ChAdOx1 nCoV-19 vaccines) [ 8 , 27 , 28 ]. This could partially explain the existence of hepatitis following vaccination without positivity for liver-associated autoantibodies ( Table 1 ) [ 8 , 10 , 12 , 13 , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature

Camacho-Domínguez

Rodríguez

Polo

et al. 2022

Journal of Translational Autoimmunity

View full text Add to dashboard Cite

Autoimmunity following COVID-19 vaccination has been reported. Herein, a 79-year-old man with clinical and immunological features of autoimmune hepatitis type 1 after ChAdOx1 nCoV-19 vaccination is presented. Clinical manifestations rapidly remitted after the instauration of immunomodulatory management. This case, together with a comprehensive review of the literature, illustrates the association between COVID-19 vaccines and the development of autoimmune conditions.

show abstract

A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Cited by 15 publications

References 15 publications

Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase

Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase

Relapse of immune thrombocytopenia after receiving AstraZeneca coronavirus disease‐2019 vaccine: A case report

COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature

Contact Info

Product

Resources

About